Argen-X - Asset Resilience Ratio

Latest as of June 2026: 15.95%

Argen-X (ARGX) has an Asset Resilience Ratio of 15.95% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Explore Argen-X long-term investment allocation to see how much of total assets are deployed in long-term investments.

Liquid Assets

€1.60 Billion

≈ $1.87 Billion USD Cash + Short-term Investments

Total Assets

€10.03 Billion

≈ $11.73 Billion USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Argen-X's Asset Resilience Ratio has changed over time. See Argen-X liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets Composition Over Time

This chart breaks down Argen-X's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Argen-X (ARGX) total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€1.60 Billion	15.95%
Total Liquid Assets	€1.60 Billion	15.95%

Asset Resilience Insights

Good Liquidity Position: Argen-X maintains a healthy 15.95% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Argen-X Industry Peers by Asset Resilience Ratio

Compare Argen-X's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Celltrion Inc KO:068270	Biotechnology	0.56%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	75.98%
Immunovant Inc NASDAQ:IMVT	Biotechnology	98.50%
Abivax SA PA:ABVX	Biotechnology	2.34%
Protagonist Therapeutics Inc NASDAQ:PTGX	Biotechnology	65.90%
Disc Medicine Inc. NASDAQ:IRON	Biotechnology	85.48%
Vericel Corp Ord NASDAQ:VCEL	Biotechnology	7.67%

Annual Asset Resilience Ratio for Argen-X (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Argen-X.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	10.93%	€948.86 Million ≈ $1.11 Billion	€8.68 Billion ≈ $10.15 Billion	-19.37pp
2024-12-31	30.29%	€1.88 Billion ≈ $2.20 Billion	€6.20 Billion ≈ $7.25 Billion	+5.39pp
2023-12-31	24.90%	€1.13 Billion ≈ $1.32 Billion	€4.54 Billion ≈ $5.31 Billion	-19.51pp
2022-12-31	44.41%	€1.39 Billion ≈ $1.63 Billion	€3.13 Billion ≈ $3.66 Billion	+9.25pp
2021-12-31	35.16%	€1.00 Billion ≈ $1.17 Billion	€2.85 Billion ≈ $3.33 Billion	+0.95pp
2020-12-31	34.20%	€779.65 Million ≈ $911.49 Million	€2.28 Billion ≈ $2.66 Billion	-28.28pp
2019-12-31	62.48%	€1.01 Billion ≈ $1.18 Billion	€1.61 Billion ≈ $1.88 Billion	+19.63pp
2018-12-31	42.85%	€283.53 Million ≈ $331.48 Million	€661.70 Million ≈ $773.60 Million	+4.89pp
2017-12-31	37.96%	€168.91 Million ≈ $197.47 Million	€444.98 Million ≈ $520.23 Million	+31.82pp
2016-12-31	6.14%	€6.83 Million ≈ $7.99 Million	€111.24 Million ≈ $130.05 Million	-7.42pp
2015-12-31	13.56%	€6.81 Million ≈ $7.97 Million	€50.25 Million ≈ $58.75 Million	-19.88pp
2014-12-31	33.44%	€23.79 Million ≈ $27.82 Million	€71.15 Million ≈ $83.18 Million	+31.44pp
2013-12-31	2.00%	€690.44K ≈ $807.19K	€34.54 Million ≈ $40.38 Million	-4.06pp
2012-12-31	6.06%	€1.39 Million ≈ $1.62 Million	€22.93 Million ≈ $26.81 Million	--

pp = percentage points

About Argen-X

BR:ARGX Belgium Biotechnology

Market Cap

$65.58 Billion

€56.09 Billion EUR

Market Cap Rank

#578 Global

#2 in Belgium

Share Price

€902.00

Change (1 day)

+1.90%

52-Week Range

€583.20 - €902.00

All Time High

€902.00